INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Corporate insider
MH

Meyer Andrew Hollman

Chief Business OfficerCIK 0001864159

EDGAR filingsOpen in network
Disclosed transactions4
Buys / sells0 / 2
Max Insider Score32
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
32
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$26K
1,879 sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Janux Therapeutics, Inc.Chief Business Officer · Nov 14, 2025
0
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
$35K
3,333 sh
Nov 14, 2025
Nov 14, 2025
traded Nov 14, 2025
+0d
SEC FORM 4

Evidence

8
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$100K
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC FORM 4

Evidence

0
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC FORM 4

Evidence

Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago